Trial Profile

Phase II Study of Combination Treatment of Methotrexate, Ibrutinib, and Temozolomide (MIT Regimen) in Patients With Newly Diagnosed Primary CNS Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Methotrexate (Primary) ; Temozolomide (Primary)
Indications CNS cancer; Lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

12 Dec 2023 Results assessing the overall response rate and safety of Methotrexate, Ibrutinib and Temozolomide (MIT) induction treatment were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
06 Apr 2022 Planned primary completion date changed from 1 Dec 2023 to 1 Sep 2022.
14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com